摘要
目的:研究血浆纤溶酶原激活物抑制剂-1(PAI-1)及其抑制剂活性(PAI-1:A)与卵巢恶性肿瘤的相关性。方法:选择来我院就诊的卵巢肿瘤患者88例,分成二组:卵巢良性肿瘤组40例,卵巢恶性肿瘤组48例,正常对照组40例。分别进行血浆纤溶酶原激活物抑制剂-1(PAI-1)及其抑制剂活性(PAI-1:A)的测定,分析比较正常组与患者组PAI-1/PAI-1:A水平的变化。结果:正常组与卵巢良性肿瘤组间比较差异无显著性(P>0.05);正常组、卵巢良性肿瘤组与卵巢恶性肿瘤(Ⅰ期)组间比较差异无显著性(P>0.05);正常组、卵巢良性肿瘤组与卵巢恶性肿瘤(Ⅱ期、Ⅲ期、Ⅳ期)组间比较差异有显著性(P<0.01)。结论:随着卵巢肿瘤恶性程度的增加,血浆纤溶酶原激活物抑制剂-1(PAI-1)含量减少,其抑制剂(PAI-1:A)活性降低,而血浆组织型纤溶酶原激活物(t-PA)含量及其活性(t-PA:A)增加。
Objective： Studying the original activated plasma fibrinolytic enzyme inhibitor - 1 （ PAI- 1 ） and its inhibitor activity （ PAI- 1 ： A ） correlated with ovarian malignant tumor. Methods： Choose 88 patients with ovarian tumors, divided into two groups ：40 cases of ovarian benign tumor group ,48 cases of ovarian malignant tumor group ,40 cases of normal control group. To test the original plasma fibrinolytic enzyme activators inhibitor - 1 （PAI - 1 ） and its inhibitor activity （PAI - 1 ： A）. Results： Comparison between the ovarian benign tumor group and normal group had no significant difference （ P 〉 0.05 ）. Normal group, ovarian benign tumors and malignant ovarian tumors （ I ） there was no significant difference between groups （P 〉 0.05 ）. Normal group, ovarian benign tumors and malignant ovarian tumors （Ⅱ period, Ⅲ period, IV period） differences were significant （ P 〈 0.01 ）. Conclusion： The ovarian malignant tumor patients plasma fibrinolytic enzyme activators inhibitor - 1 （PAl - 1 ） and its inhibitor activity （PAI - 1 ：A） are increased with the degree of malignant ovarian tumors, the original plasma fibrinolytic enzyme activators inhibitor - 1 （ PAI- 1 ） content reduced and its inhibitor （ PAl - 1 ： A） activity is reduced, the original tissue and plasma fibrino- lytic enzyme activators （t- PA） content increased and its active （t- PA：A） also increased.
出处
《现代肿瘤医学》
CAS
2015年第8期1119-1121,共3页
Journal of Modern Oncology
